Mark DeLong
Corporate Officer/Principal at APELLIS PHARMACEUTICALS, INC.
Net worth: 3 M $ as of 29/04/2024
Profile
Mark DeLong is currently the Chief Business & Strategy Officer at Apellis Pharmaceuticals, Inc. He previously worked at EMD Serono, Inc. as the Head of Business Development from 2007 to 2018.
Mr. DeLong completed his undergraduate degree at The Pennsylvania State University and holds an MBA from the University of Michigan.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
17/03/2024 | 54,693 ( 0.05% ) | 3 M $ | 29/04/2024 |
Mark DeLong active positions
Companies | Position | Start |
---|---|---|
APELLIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 31/01/2018 |
Former positions of Mark DeLong
Companies | Position | End |
---|---|---|
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Corporate Officer/Principal | 31/12/2017 |
Training of Mark DeLong
The Pennsylvania State University | Undergraduate Degree |
University of Michigan | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
APELLIS PHARMACEUTICALS, INC. | Health Technology |
Private companies | 1 |
---|---|
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Health Technology |
- Stock Market
- Insiders
- Mark DeLong